Amylyx Pharmaceuticals, Inc.
AMLX
Clasificación en acciones
#4618
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Precio por acción
$26.28
Última sincronización: 2026-10-16
Capitalización bursátil
$3.30B
Cambio (1 día)
-4.95%
Cambio (1 año)
75.79%
País
US
Comercio Amylyx Pharmaceuticals, Inc. (AMLX)
Categoría
Healthcare
EPS de Amylyx Pharmaceuticals, Inc. (AMLX)
EPS a fecha de June 2026 TTM: $-1.41
Según los últimos informes financieros y el precio de las acciones de Amylyx Pharmaceuticals, Inc., el EPS actual de la empresa (TTM) es $-1.41. Al final del año 2023, la empresa tenía un EPS de $0.73 un aumento con respecto a al EPS de 2022, que fue de $-2.98.
Historial de EPS de Amylyx Pharmaceuticals, Inc. desde 2019 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
